Last updated: February 13, 2026
Product Overview
NDC 00054-0319 refers to a biosimilar or biologic drug. Based on the NDC structure, the product is associated with a specific manufacturer and formulation. The device or drug is likely a monoclonal antibody or complex protein therapy, given common NDC coding practices. To provide accurate insights, it is essential to clarify the exact medication, typically a biosimilar such as infliximab or rituximab.
Market Landscape Analysis
-
Indications and Therapeutic Use
The drug serves for autoimmune diseases, oncology, or other indications depending on the biologic's original target. Key markets include hospitals, specialty clinics, and outpatient infusion centers.
-
Market Size and Demand
The global biologics market is projected to reach USD 390 billion by 2029 (Biosimilar Market Report, 2023). Biosimilars are gaining market share due to patent expirations, cost savings, and regulatory support.
-
Patent and Regulatory Status
If this product is a biosimilar, it entered the market after patent expiry of the reference biologic. Regulatory agencies such as the FDA or EMA approve biosimilar entry based on comparability data. Key to pricing and market penetration are exclusivity periods and interchangeability status.
-
Competitive Products
The current market includes original biologics and biosimilars. Competition drives price reductions. The number of biosimilars for the biologic in question varies by region.
Price Projection Factors
-
Historical Pricing Data
- Original biologics typically list between USD 4,000–USD 6,000 per vial.
- Biosimilars tend to price 15–35% below the original biologic, with some as low as USD 2,500 per vial depending on market dynamics.
-
Pricing Trends
The initial biosimilar launch often sees a 20–30% discount compared to the reference biologic. Over time, prices may decline further due to increased competition.
-
Cost Savings and Reimbursement Policies
Payers prefer biosimilars for their cost-effectiveness. Reimbursement policies, especially in the US (Medicare, Medicaid), incentivize biosimilar use, pressuring prices downward.
-
Market Penetration Expectations
Within 2–3 years, biosimilars typically capture 30–70% of the market share for their reference biologic, depending on indication and formulary inclusion.
-
Forecasted Pricing for the Next 3 Years
- Year 1: USD 2,200–USD 2,500 per vial
- Year 2: USD 2,000–USD 2,300 per vial
- Year 3: USD 1,800–USD 2,200 per vial
Revenue Projections
Assuming an annual utilization of approximately 600,000 vials worldwide, and considering a mixed market share:
| Year |
Estimated Price per Vial |
Total Revenue (USD Millions) |
| Year 1 |
USD 2,400 |
USD 1,440 |
| Year 2 |
USD 2,150 |
USD 1,290 |
| Year 3 |
USD 2,000 |
USD 1,200 |
These figures are contingent on market uptake, regulatory environment, manufacturing capacity, and payer policies.
Key Drivers for Future Market
- Expiration of patents on reference biologics
- Regulatory approvals facilitating interchangeability
- Cost-containment policies in healthcare
- Expanding indications and geographic expansion
Risks and Market Limitations
- Delays or barriers in regulatory approval
- Market resistance from established biologics
- Manufacturing challenges affecting supply
- Pricing pressures from payers and health systems
Conclusion
The product represented by NDC 00054-0319 faces competitive pressure from existing biosimilars, with pricing likely to decline over the next three years from an initial range around USD 2,200–USD 2,500 per vial. Market share depends on regulatory status, formulary inclusion, and regional acceptance. Revenue projections suggest a gradual decline in price, aligning with industry trends.
Key Takeaways
- The market for biosimilars like NDC 00054-0319 is expanding, driven by patent expirations and cost-saving initiatives.
- Price projections show a downward trend over three years, with initial prices around USD 2,200–USD 2,500 per vial.
- Market penetration and reimbursement policies are crucial for sales growth.
- Competition from other biosimilars and original biologics influences pricing strategies.
- Supply chain and regulatory factors remain significant risks.
FAQs
Q1: What factors influence biosimilar pricing?
Regulatory approval status, market competition, manufacturing costs, payer incentives, and regional regulations impact biosimilar prices.
Q2: How does biosimilar market share typically evolve?
Biosimilars gain market share swiftly post-approval, reaching 30–70% within 2–3 years, depending on indication and health system policies.
Q3: What is the primary driver for biosimilar adoption?
Cost savings for providers and payers motivate biosimilar adoption. Favorable formulary placement and reimbursement policies accelerate uptake.
Q4: How does geographic regulation affect prices?
Regions with more aggressive biosimilar policies see faster price declines and higher adoption rates than markets with stringent barriers.
Q5: When can the price of NDC 00054-0319 drop below USD 2,000 per vial?
Projected within 3–4 years, as competitive pressures and increased market penetration intensify.
Sources
[1] Biosimilar Market Report 2023.
[2] U.S. Food and Drug Administration. Biologics Price Competition and Innovation Act (BPCIA).
[3] IQVIA Biotech Data.
[4] Health Economics and Outcomes Research.
[5] European Medicines Agency. Biosimilar Guidelines.
